DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension

Information source: Allergan
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Glaucoma; Ocular Hypertension

Intervention: Brimonidine ophthalmic solution 0.1% (Drug); Brimonidine ophthalmic solution 0.2% (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Allergan

Official(s) and/or principal investigator(s):
Medical Director, Study Director, Affiliation: Allergan


This study evaluates the safety and efficacy of brimonidine 0. 1% ophthalmic solution compared with brimonidine 0. 2% ophthalmic solution in patients with glaucoma or ocular hypertension

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Intraocular pressure (IOP)

Secondary outcome: IOP


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Ocular hypertension or glaucoma in both eyes

Exclusion Criteria:

- Uncontrolled systemic disease

- Known allergy or sensitivity to brimonidine

Locations and Contacts

Atlanta, Georgia, United States
Additional Information

Link to Clinical Trial Results

Starting date: May 2003
Last updated: April 1, 2008

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017